A federal judge has cleared the way for a major antitrust lawsuit accusing five of America's largest health insurers of conspiring to suppress provider payments.
On March 30, 2026, the United States District Court for the District of Massachusetts denied a joint motion to dismiss filed by Zelis Healthcare and commercial payer defendants Aetna, The Cigna Group, Elevance Health Companies, Humana, and UnitedHealth Group.
At the heart of the dispute is Zelis, a healthcare technology company that provides network management, claims integrity, and payment solutions to insurers. The plaintiffs are a group of healthcare providers from across the country, including a California medical group of approximately 100 doctors and healthcare professionals, dental practices in Kansas and Wisconsin, a solo otolaryngologist in New Jersey, a chiropractic practice in California, and an additional consolidated plaintiff. Together, they allege that Zelis and the five insurers worked together to drive down what providers are paid for out-of-network care.
The mechanism, according to the complaint, involves two Zelis repricing tools. One, called the Established Reimbursement Solution, generates a fee schedule based on market payment rates. The plaintiffs argue this tool is built on in-network rate data, making it a poor and downwardly skewed benchmark for out-of-network claims. The other, Reference Based Pricing, simply caps reimbursement at pre-set levels. Insurers use both tools to reprice provider claims and offer lower payment amounts.
The providers say the result is a system where they are left with little real choice: accept the slashed payment, try to negotiate with Zelis in what they describe as a one-sided process, or file an appeal that rarely changes the outcome. One plaintiff, Pacific Inpatient Medical Group, alleges that a claim it submitted was repriced at a discount of more than 88 percent. Zelis, for its part, earns a cut of the savings – it receives a percentage of the gap between what a provider bills and what is actually paid.
The complaint alleges that the practice has cut some providers' out-of-network revenue by half or more, forcing some practitioners to consider other business arrangements or to close entirely. The plaintiffs also contend that despite shrinking payments to providers, insurance premiums have continued to rise, meaning patients are not seeing any benefit either.
The defendants mounted a broad challenge to the case, attacking everything from standing to market definition. On standing, they argued the court should evaluate each plaintiff and each claim separately. The court disagreed, finding that since all six plaintiffs are bringing a single antitrust claim based on the same alleged conduct and harm, the case can move forward so long as at least one plaintiff has standing.
The insurers also argued that the providers' injuries were not directly caused by the repricing tools, pointing out that providers could negotiate higher rates or bill patients directly for the difference. The court was not persuaded, noting that the complaint alleges providers are effectively unable to negotiate and are prohibited from balance-billing patients. At the motion-to-dismiss stage, the court said, those allegations must be taken at face value.
On the question of whether the providers suffered the kind of harm antitrust law is designed to address, the defendants characterized the situation as simply producing lower healthcare costs – something, they argued, that benefits consumers. The court rejected that framing, citing established precedent that suppliers forced to accept artificially depressed prices by a group of powerful buyers can claim antitrust injury, even when end consumers are not directly harmed. The court emphasized that it is the free play of competitive forces, rather than coordinated price suppression, that the law recognizes as the proper mechanism for benefiting consumers.
The conspiracy allegations run along two tracks. The first is a traditional horizontal conspiracy, in which the plaintiffs allege that Zelis and the insurers are competitors in the market for out-of-network services and agreed to fix prices. The defendants countered that Zelis is merely a technology vendor, not a competitor. But the court found that the complaint specifically alleges Zelis itself purchases out-of-network healthcare services, placing it in the same market as the insurers – a key distinction from the parallel MultiPlan litigation in Illinois, where the horizontal conspiracy theory faltered because there were no similar allegations that MultiPlan purchased out-of-network services.
The second theory is a hub-and-spoke conspiracy, with Zelis at the center and the insurers as the spokes. The court found that the plaintiffs had laid out enough circumstantial evidence to support this theory, including the parallel adoption of Zelis's tools by competing insurers, the sharing of competitively sensitive claims data through Zelis, and the fact that any single insurer adopting the tools unilaterally would risk losing subscribers as providers stopped accepting their patients.
The defendants also challenged the plaintiffs' definition of the relevant market, arguing that out-of-network services are too broad a category and that a nationwide geographic market is inappropriate. The court found both definitions plausible at this stage, noting that market definition is a deeply fact-intensive question not easily resolved on a motion to dismiss.
Humana raised its own arguments, pointing out that the complaint acknowledges it stopped selling the commercial health insurance products at issue in this case in 2024. The court found this did not shield Humana from liability for its alleged participation in the conspiracy prior to that point, which the plaintiffs say began on or around June 13, 2016.
In a separate ruling on March 4, 2026, the court granted motions by Aetna, UnitedHealth, and Elevance to compel arbitration against certain plaintiffs, staying those specific claims.
The case now enters discovery, where the competing narratives – whether Zelis is simply a cost-management tool or the engine of a price-fixing scheme – will be tested against the evidence. For insurers, the stakes extend well beyond this single lawsuit. A finding of conspiracy could reshape how the industry handles out-of-network repricing, a practice that has become deeply embedded in commercial health insurance operations nationwide.
